[Sertindole, a novel alpha 1A-adrenoceptor selective antagonist]

¹Institute of Vascular Medicine, Third Hospital, Beijing Medical University, Beijing 100083.

|July 1, 1997

Summary

Sertindole selectively antagonizes alpha 1A-adrenergic receptors (alpha 1-ARs) irreversibly and competitively. This finding suggests sertindole

Area of Science:

Context:

Alpha-1 adrenergic receptors (alpha 1-ARs) are critical in regulating vascular tone.
Understanding subtype-specific receptor interactions is key for developing targeted therapeutics.
Sertindole's interaction with alpha 1-AR subtypes was previously unclear.

Purpose:

To investigate the antagonistic effects of sertindole on cloned alpha 1A, alpha 1B, and alpha 1D-AR subtypes.
To determine the selectivity and mechanism of sertindole's interaction with alpha 1-ARs.
To correlate in vitro binding data with in vivo functional responses.

Summary:

Radioligand binding assays revealed sertindole has significantly higher affinity for alpha 1A-AR compared to alpha 1B- and alpha 1D-AR.
Functional studies showed sertindole antagonized norepinephrine-induced vasoconstriction in rat aorta and renal artery, aligning with alpha 1A- and alpha 1D-AR affinities.
Sertindole treatment reduced maximal binding capacity (Bmax) without altering affinity (KD) for 125I-IBE2254, indicating irreversible antagonism.

Impact:

Sertindole is identified as a selective, irreversible, competitive antagonist, primarily targeting the alpha 1A-AR subtype.
This research provides a molecular basis for sertindole's pharmacological profile.
Findings may inform the development of novel drugs targeting alpha 1-ARs for cardiovascular conditions.

Related Experiment Videos